AOCOPM 2024 Midyear Educational Conference-Q - Obesity: New Injectables' Implications and Use

Q - Obesity: New Injectables' Implications and Use - Nicholas Pennings, DO, FOMA, FACOFP

Video Transcription

Video Summary

Dr. Penning, an associate professor and family medicine expert, delivered the prestigious Murray Goldstein Commemorative Lecture at the Mid-Year Convention of the American Osteopathic College of Occupational and Preventive Medicine, where he discussed advancements in obesity medicine. With a focus on incretins, such as GLP-1 agonists, Dr. Penning explored their expanded role from diabetes management to effective obesity treatment. Discussing the evolution of obesity medications, he highlighted key studies showcasing significant weight loss and health benefits, akin to those of bariatric surgery. He also indicated the potential risks and lifestyle adjustments needed, such as dietary changes and physical activity to minimize muscle mass loss. Furthermore, he showcased the ongoing research and promising future of obesity treatments, including novel drug classes and combinations that might improve outcomes for related conditions like cardiovascular disease and fatty liver. Dr. Penning concluded by recognizing the impact of these advancements in revolutionizing obesity medicine, improving patient health outcomes, and shifting the medical approach to treating obesity as enduring, multifaceted disease.

Keywords

obesity medicine

incretins

GLP-1 agonists

weight loss

bariatric surgery

dietary changes

cardiovascular disease

fatty liver

novel drug classes